Literature DB >> 1661629

Pharmacological studies on otilonium bromide.

A Giachetti1.   

Abstract

Otilonium bromide (OB) is a quaternary ammonium compound characterized by a long aliphatic chain. Its chemical properties are responsible for both a poor penetration in CNS and a prolonged binding to cell membranes. OB is a spasmolytic agent which acts by modifying Ca++ fluxes from extra and intracellular sites. It has been documented that iv administration (10 mg/kg) of OB causes a marked reduction of colonic motility lasting from 2 to 3 hours, whereas an inhibition of upper GI motor activity is present only at higher dosages. In conclusion, OB seems to exert its activity mainly on distal GI tract, and its spasmolytic effect may be due to its ability to inhibit Ca++ fluxes and to a direct action of the drug on the contractile proteins of the smooth muscle.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1661629

Source DB:  PubMed          Journal:  Ital J Gastroenterol        ISSN: 0392-0623


  3 in total

1.  Changes in nitrergic and tachykininergic pathways in rat proximal colon in response to chronic treatment with otilonium bromide.

Authors:  G Cipriani; S J Gibbons; S A Saravanaperumal; J Malysz; L Sha; J H Szurszewski; D R Linden; S Evangelista; M S Faussone-Pellegrini; M G Vannucchi; G Farrugia
Journal:  Neurogastroenterol Motil       Date:  2015-04-30       Impact factor: 3.598

2.  Otilonium: a potent blocker of neuronal nicotinic ACh receptors in bovine chromaffin cells.

Authors:  L Gandía; M Villarroya; B Lara; V Olmos; J A Gilabert; M G López; R Martínez-Sierra; R Borges; A G García
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

3.  Effect of herbal extract granules combined with otilonium bromide on irritable bowel syndrome with diarrhoea: a study protocol for a randomised controlled trial.

Authors:  Joong Il Kim; Pumsoo Kim; Jin-Hyun Lee; Yoo-Jin Kim; Na-Rae Yang; Myong Ki Baeg; Ja Sung Choi; Hye-Jung Kim; Jayoung Kim; Yun-Young Sunwoo; Jung-Han Lee; Hyekyung Ha; Tae-Yong Park
Journal:  BMJ Open       Date:  2017-12-01       Impact factor: 2.692

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.